AP Biosciences Sets Global Stage for Novel Cancer Drug AP505

TAIPEI, Taiwan – March 30, 2026 – In a strategic move poised to reshape its future, clinical-stage biopharmaceutical company AP Biosciences has finalized an amended collaboration agreement with Tasly Pharmaceutical Group, setting the stage for the global out-licensing of its promising cancer therapy, AP505 (B1962). The revised deal creates a clear pathway for the innovative bispecific antibody to enter international markets beyond its original territory of mainland China, Hong Kong, and Macau, potentially bringing a new class of treatment to patients with advanced solid tumors worldwide.

This amendment transforms a regional partnership into a global launchpad. It leverages Tasly’s successful and efficient clinical development of AP505 within China to attract major international pharmaceutical partners. For AP Biosciences, a company focused on next-generation antibody therapies, this is a pivotal step from being a regional innovator to becoming a significant player on the global oncology stage. The deal, advised by Locust Walk Partners, LLC, signals that AP505 is ready for primetime and that discussions with potential global suitors can now begin in earnest.

A Strategic Pivot to the Global Stage

The original agreement, signed in July 2019, granted Tasly exclusive rights to develop and commercialize AP505 in Greater China. This partnership was fruitful, yielding an upfront payment of $4.5 million for AP Biosciences and, more importantly, leading to significant clinical progress. Tasly has since guided AP505 through a successful Phase 1 trial and into two ongoing Phase 2 trials for advanced solid tumors, which commenced in early 2025.

Today's announcement fundamentally expands the drug’s horizon. The amendment establishes a framework designed to accelerate AP505's journey to patients in major markets like the United States, Europe, and Japan. Under the new terms, Tasly will actively support AP Biosciences' global partnering efforts by providing a comprehensive package of clinical data, regulatory materials, and a stable clinical drug supply—all on a revenue-sharing basis. This structure de-risks the asset for potential licensees, offering them a mature candidate with a substantial data package generated from Tasly's in-territory work.

“This amendment reflects the shared commitment between AP Biosciences and Tasly to accelerate the development and commercialization of AP505 (B1962) for patients globally,” said Jeng Her, Ph.D., Founder and Chief Executive Officer of AP Biosciences, in the official announcement. “By establishing clear and rapid pathways for technology transfer, clinical data sharing, and clinical supply, this agreement enhances our readiness to engage potential partners and progress AP505 (B1962) toward ex-Territory clinical development.”

This move is particularly critical for a clinical-stage company like AP Biosciences. Securing a global licensing deal would not only provide a significant infusion of non-dilutive capital through upfront and milestone payments but also validate its proprietary T-cube and Omni-Mab technology platforms. Industry sources suggest that AP Biosciences is already courting “over five top-15 global pharma companies,” indicating strong preliminary interest in the asset.

The Science Behind AP505: A Dual-Pronged Attack on Cancer

What makes AP505 so attractive is its innovative design. The drug is a bispecific antibody engineered to simultaneously block two critical pathways that tumors use to grow and evade the immune system: PD-L1 and VEGF.

• Unleashing the Immune System: By binding to PD-L1, a protein often found on the surface of cancer cells, AP505 prevents the tumor from switching off an immune attack. This action effectively releases the brakes on T cells, allowing them to recognize and destroy cancerous cells.
• Starving the Tumor: At the same time, AP505 targets VEGF, a signaling protein that fuels angiogenesis—the creation of new blood vessels that tumors need to grow and metastasize. By cutting off this blood supply, the antibody aims to inhibit tumor growth and survival.

This dual-action mechanism represents a significant evolution from conventional monotherapies. While single-agent immunotherapies have revolutionized cancer care, they have shown limited efficacy in certain notoriously difficult-to-treat cancers. AP505 is specifically being developed for indications like hepatocellular carcinoma (HCC) and pMMR colorectal cancer (CRC), where combining immune checkpoint inhibition with anti-angiogenic effects in a single molecule could offer a superior therapeutic outcome.

The drug’s symmetric, IgG-based structure also provides key manufacturing and stability advantages, making it a more practical and scalable option compared to some other complex biologic formats. With Phase 1 trials complete and Phase 2 studies underway for a range of solid tumors—including lung, breast, and cervical cancer in addition to CRC and HCC—AP505 has a growing body of clinical evidence supporting its potential.

A New Blueprint for Cross-Border Collaboration

The amended AP Biosciences-Tasly agreement is more than just a standard licensing deal; it represents an evolving model of East-West biopharma collaboration. In this framework, the regional partner’s development work becomes a strategic asset for global expansion. Tasly’s “proven clinical development efficiency” is not just benefiting patients in China but is now the foundation for a global commercialization strategy.

This symbiotic relationship allows each party to play to its strengths. AP Biosciences retains control of the global strategy and can negotiate from a position of strength, armed with robust clinical data. Tasly, in turn, secures a stake in the global success of a drug it helped advance, turning its regional expertise into a share of worldwide revenue. This model of leveraging in-territory data to fuel ex-territory partnering is becoming increasingly popular as it accelerates timelines and maximizes the value of an asset.

Navigating a Competitive and Lucrative Market

AP Biosciences is entering the global licensing arena at a time of intense interest and investment in bispecific antibodies. The market, valued at over $15 billion in 2025, is projected by some analysts to explode to over $400 billion by 2035. Oncology applications are the primary driver of this growth, with major pharmaceutical companies like Roche, Amgen, and Sanofi aggressively pursuing novel bispecific assets to bolster their pipelines.

AP505 will face competition from other molecules in development, including those targeting the same PD-1/VEGF pathways. However, its advancement into Phase 2 trials gives it a competitive edge over earlier-stage assets. The North American market, which accounts for the largest share of immunotherapy sales, will be a key target. The FDA has established clear regulatory pathways for such innovative therapies, and the high unmet need in AP505’s target indications creates a significant market opportunity.

The decision to formally structure the global out-licensing path now is a calculated one. With compelling Phase 1 data in hand and multiple Phase 2 trials generating further evidence, AP505 is at an ideal inflection point to attract a deep-pocketed global partner capable of funding pivotal late-stage trials and navigating the complex commercial launch process. This amended agreement effectively fires the starting gun on that global race.